Enhancement of depsipeptide-mediated apoptosis of lung or esophageal cancer cells by flavopiridol: Activation of the mitochondria-dependent death-signaling pathway

Journal of Thoracic and Cardiovascular Surgery

Volumn 125, Issue 5, 2003, Pages 1132-1142

  Nguyen, Dao M ^a   Schrump, William D ^b   Tsai, Wilson S ^b   Chen, Aaron ^b   Stewart IV, John H ^b   Steiner, Federico ^b   Schrump, David S ^b   Swisher, Stephen G ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

DEPSIPEPTIDE; FLAVOPIRIDOL;

APOPTOSIS; ARTICLE; CANCER CELL; CELL DEATH; CYTOTOXICITY; ENZYME ACTIVATION; EPITHELIUM CELL; ESOPHAGUS CANCER; HUMAN; HUMAN CELL; LUNG CANCER; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NICK END LABELING; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

EID: 0037674946     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1067/mtc.2003.180     Document Type: Article

References (22)

1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced nonsmall-cell lung cancer. N Engl J Med. 2002;346:92-8.
2. Ueda H, Manda T, Matsumoto S, Mukumoto S, Nishigaki F, Kawamura I, Shimomura K. FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No 968. Antitumor activities on experimental tumors in mice. J Antibiot. 1994;47:315-23.
3. Sandor V, Senderowicz A, Mertins S, Sackett D, Sausville E, Blagosklonny MV, et al. P21-dependent g(1)arrest with downregulation of cyclin D1 and upregulation of cyclin E by the histone deacetylase inhibitor FR901228. Br J Cancer. 2000;83:817-25.
4. Sambucetti LC, Fischer DD, Zabludoff S, Kwon PO, Chamberlin H, Trogani N, et al. Histone deacetylase inhibition selectively alters the activity and expression of cell cycle proteins leading to specific chromatin acetylation and antiproliferative effects. J Biol Chem. 1999; 274:34940-7.
5. Burgess AJ, Pavey S, Warrener R, Hunter LJ, Piva TJ, Musgrove EA, et al. Up-regulation of p21(WAF1/CIP1) by histone deacetylase inhibitors reduces their cytotoxicity. Mol Pharmacol. 2001; 60:828-37.
6. Schrump DS, Matthews W, Chen GA, Mixon A, Altorki NK. Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 1998;4:2885-90.
7. Cartee L, Wang Z, Decker RH, Chellappan SP, Fusaro G, Hirsch KG, et al. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cancer Res. 2001;61:2583-91.
8. Rosato RR, Wang Z, Gopalkrishnan RV, Fisher PB, Grant S. Evidence of a functional role for the cyclin-dependent kinase-inhibitor p21WAF1/ CIP1/MDA6 in promoting differentiation and preventing mitochondrial dysfunction and apoptosis induced by sodium butyrate in human myelomonocytic leukemia cells (U937). Int J Oncol. 2001;19:181-91.
9. Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl2 heterodimerizes in vivo with a conserved homolog Bax, that accelerates programmed cell death. Cell. 1993;74:609-19.
10. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES, et al. Cytochrome c and dATP-dependent formation of Apaf-I/caspase-9 complex initiates an apoptotic protease cascade. Cell. 1997; 91:479-89.
11. Sandor V, Bakke S, Robey RW, Kang MH, Blagosklonny MV, Bender J, et al. Phase I trial of the histone deacetylase inhibitor, depsipeptide (FR901228, NSC 630176), in patients with refractory neoplasms. Clin Cancer Res. 2002;8:718-28.
12. Yu X, Guo ZS, Marcu MG, Neckers L, Nguyen DM, Chen GA, Schrump DS. Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst. 2002;94:504-13.
13. Senderowicz AM, Headlee D, Stinson SF, Lush RM, Kalil N, Villalba L, et al. Phase I trial of continuous infusion flavopiridol, a novel cyclin-dependent kinase inhibitor, in patients with refractory neoplasms. J Clin Oncol. 1998;16:2986-99.
14. Schwartz GK, Ilson D, Saltz L, O'Reilly E, Tong W, Maslak P, et al. Phase II study of the cyclin-dependent kinase inhibitor flavopiridol administered to patients with advanced gastric carcinoma. J Clin Oncol. 2001;19:1985-92.
15. Shapiro GI, Koestner DA, Matranga CB, Rollins BJ. Flavopiridol induces cell cycle arrest and p53-independent apoptosis in nonsmall cell lung cancer cell lines. Clin Cancer Res. 1999;5:2925-38.
16. Byrd JC, Shinn C, Ravi R, Willis CR, Waselenko JK, Flinn IW, et al. Depsipeptide (FR901228): a novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood. 1999;94:1401-8.
17. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. Two CD95 (APO-1/Fas) signaling pathways. EMBO J. 1998;6:1675-87.
18. Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the Bcl2 family and cell death. Blood. 1996;88:386-401.
19. Wei MCX, Zong W-X, Cheng EHY, Lindsten T, Panoutsakopoulou V, Ross AJ, et al. Proapoptotic Bax and Bak: a requisite gateway to mitochondria dysfunction and death. Science. 2001;292:727-30.
20. Adams JM, Cory S. The Bcl-2 protein family: arbiters of cell survival. Science. 1998;281:1322-6.
21. Suzuki A, Tsutomi Y, Miura M, Akahanie K. Caspase 3 activation to suppress Fas-mediated apoptosis: identification of a binding domain with p21 and ILP and inactivation machinery by p21. Oncogene. 1999;18:1239-44.
22. Engels H, Stepczynska AQ, Stroh C, Lauber K, Berg C, Schwenzer R, et al. Caspase 8/FLICE functions as an executioner caspase in anticancer drug-induced apoptosis. Oncogene. 2000;19:4563-73.